Epix Medical president and COO Dr. Stephen Knight has left the Cambridge, MA-based company to become president of Fidelity Investments unit Fidelity Biosciences Group.
Knight will remain with the company, however, through Epix’s new drug application (NDA) submission for MS-325, an MR angiography contrast agent. CEO Michael Webb will add the role of president to his duties.
In other Epix news, the company reported positive results from phase II trials of MS-325. The agent was well-tolerated by patients with varying degrees of renal impairment, including those requiring dialysis, and had no adverse effect on renal function, Epix said.
By AuntMinnie.com staff writersNovember 11, 2003
Related Reading
Epix continues to build revenues, trim losses in Q3, October 24, 2003
Epix to present phase III results, September 15, 2003
Epix exercises overallotment option, August 27, 2003
Epix sets share price, August 7, 2003
Epix to offer more shares, July 28, 2003
Copyright © 2003 AuntMinnie.com